Recent Findings in N6-Methyladenosine Modification and Significance in Pancreatic Cancer

Hara, Tomoaki; Meng, Sikun; Arao, Yasuko et al.

Cancer Medicine, 2025, 14(11), e70934

Number of Access:6（2025-08-16 03:18 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/102236

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
CancerMed_14_11_e70934 pdf None 467 KB 14 2025.07.10  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Recent Findings in N6-Methyladenosine Modification and Significance in Pancreatic Cancer
Creator
NRID
1000030779161 1000030779161
researchmap permalink
registered20221012 registered20221012
CreatorName
Hara, Tomoaki
NRID
1000050977204 1000050977204
researchmap permalink
sikunmeng sikunmeng
CreatorName
Meng, Sikun
NRID
1000070962736 1000070962736
CreatorName
Arao, Yasuko
CreatorName
Saito, Yoshiko
CreatorName
Inoue, Kana
CreatorName
Rennie, Sarah
CreatorName
Ofusa, Ken
NRID
1000040314322 1000040314322
researchmap permalink
torumd torumd
CreatorName
Kitagawa, Toru
NRID
1000010280736 1000010280736
researchmap permalink
read0103186 read0103186
Scopus Author ID
7402978600 7402978600
CreatorName
Ishii, Hideshi
Subject
m6A
METTL3
pancreatic cancer
RNA modifications
TCEAL8
Description
Hara T., Meng S., Arao Y., et al. Recent Findings in N6-Methyladenosine Modification and Significance in Pancreatic Cancer. Cancer Medicine 14, e70934 (2025); https://doi.org/10.1002/cam4.70934.
Abstract
Background: RNA modifications are widely detected in cells and are involved in RNA structural stabilization and regulation of gene expression. In cancer cells, RNA modifications are altered, resulting in abnormal expression of numerous genes and promoting cancer growth. N1-methyladenosine (m¹A), N6-methyladenosine (m⁶A), N3-methylcytosine (m³C), 5-methylcytosine (m⁵C), 7-methylguanosine (m⁷G), and N4-acetylcytidine (ac⁴C) have been reported as RNA modifications affecting gene expression. Aim: In this review, the function of m⁶A in pancreatic cancer is mainly described, and the current status and prospects of RNA modifications are discussed. Methodology: We summarize recent reports on m⁶A writers METTL3, METTL5, METTL14, and METTL16; m⁶A readers IGF2BP1, IGF2BP2, IGF2BP3, YTHDF1, YTHDF2, and YTHDF3; and m⁶A erasers ALKBH5 and FTO. Results: RNA modifications are written to the RNA by the writer, and the reader binds to the RNA modification, causing gene expression to increase or decrease. Gene expression is also regulated by the removal of RNA modifications by the eraser. Moreover, our recent investigation into m⁶A modifications in pancreatic cancer has led to the identification of several promising candidate biomarkers, highlighting the potential role of epitranscriptomic regulation in tumorigenesis. Conclusion: These findings suggest that further exploration of RNA modification functions may facilitate the identification of novel biomarker and therapeutic target molecules for pancreatic cancer.
Publisher
John Wiley and Sons Inc
Source Title
Cancer Medicine
Volume (Issue)
14(11)
Page
e70934
Date of Issued
2025-03-25
Language
English
Handle URL
https://hdl.handle.net/11094/102236
eISSN
20457634
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1002/cam4.70934
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article